Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrin αvβ3–Targeted Radiotracer 99mTc-3P-RGD2

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2013-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.112.202622PMID 23750021PMCID PMC3716312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin αvβ3.

  2013cited by this paper
• A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model

  2012cited by this paper
• Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

  2012cited by this paper
• 99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study

  2012cited by this paper
• Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy

  2012cited by this paper
• Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2

  2012influential reference
• ABT-869, a Multitargeted Receptor Tyrosine Kinase Inhibitor, Reduces Tumor Microvascularity and Improves Vascular Wall Integrity in Preclinical Tumor Models

  2011cited by this paper
• Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.

  2011cited by this paper
• Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy

  2011cited by this paper
• Tumor angiogenesis: molecular pathways and therapeutic targets

  2011cited by this paper
• 99mTc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin αvβ3 Expression

  2011influential reference
• Evaluation of 111In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability

  2011cited by this paper
• Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates

  2011cited by this paper
• The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

  2011cited by this paper
• Forty-Year Journey of Angiogenesis Translational Research

  2011cited by this paper
• 18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy

  2011cited by this paper
• Monitoring Tumor Response to Antiangiogenic Sunitinib Therapy with 18F-Fluciclatide, an 18F-Labeled αVβ3-Integrin and αVβ5-Integrin Imaging Agent

  2011cited by this paper
• Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.

  2010influential reference
• Integrins in cancer: biological implications and therapeutic opportunities

  2010cited by this paper
• Integrins in cancer: biological implications and therapeutic opportunities

  2010cited by this paper
• 99mTcO(MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics

  2009cited by this paper
• Biomarkers of response and resistance to antiangiogenic therapy

  2009cited by this paper
• Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.

  2009cited by this paper
• ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

  2009cited by this paper
• 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics.

  2009cited by this paper
• Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.

  2009cited by this paper
• Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma.

  2008cited by this paper
• Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy

  2008cited by this paper
• Integrin and Growth Factor Receptor Alliance in Angiogenesis

  2008cited by this paper
• DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

  2007cited by this paper
• ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

  2007cited by this paper
• Mechanisms of Integrin–Vascular Endothelial Growth Factor Receptor Cross-Activation in Angiogenesis

  2007cited by this paper
• Differential diagnosis of solitary pulmonary nodules based on 99mTc-EDDA/HYNIC-TOC scintigraphy: the effect of tumour size on the optimal method of image assessment

  2006cited by this paper
• Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.

  2005cited by this paper
• Angiogenesis as a therapeutic target

  2005cited by this paper
• Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

  2005cited by this paper
• Imaging tumour angiogenesis

  2005cited by this paper
• Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer.

  2004cited by this paper
• Angiogenic and angiostatic factors in the molecular control of angiogenesis.

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Platelet-derived Growth Factor Receptor β and Vascular Endothelial Growth Factor Receptor 2 Bind to the β3Integrin through Its Extracellular Domain*

  2000cited by this paper
• Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain.

  2000cited by this paper
• Growth Factors in Glioma Angiogenesis: FGFs, PDGF, EGF, and TGFs

  2000cited by this paper
• Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor‐2

  1999cited by this paper
• Synthetic αVβ3 Antagonists Inhibit Insulin-Like Growth Factor-I-Stimulated Smooth Muscle Cell Migration and Replication1.

  1999cited by this paper
• Synthetic alphaVbeta3 antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication.

  1999cited by this paper
• Signal transduction via platelet-derived growth factor receptors.

  1998cited by this paper
• The synergistic activity of α v β 3 integrin and PDGF receptor increases cell migration

  1998cited by this paper
• The synergistic activity of alphavbeta3 integrin and PDGF receptor increases cell migration.

  1998cited by this paper
• Regulation of Tenascin-C, a Vascular Smooth Muscle Cell Survival Factor that Interacts with the αvβ3 Integrin to Promote Epidermal Growth Factor Receptor Phosphorylation and Growth

  1997cited by this paper
• Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.

  1997cited by this paper
• Function and Regulation of the β3 Integrins in Hemostasis and Vascular Biology

  1995cited by this paper
• Extracellular matrix modulates epidermal growth factor receptor activation in rat glomerular epithelial cells.

  1994cited by this paper

• Achievements in active agent structures as a power tools in tumor angiogenesis imaging.

  2021cites this paper
• 99mTc-3PRGD2 SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft Animals

  2019cites this paper
• An optimized LC-MS/MS method for determination of HYNIC-3PRGD2, a new promising imaging agent for tumor targeting, in rat plasma and its application.

  2018cites this paper
• 99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma

  2018cites this paper
• Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

  2017cites this paper
• Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging.

  2016cites this paper
• Simultaneous SPECT imaging of multi-targets to assist in identifying hepatic lesions

  2016cites this paper
• Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging

  2016influential citation
• Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy.

  2016cites this paper
• Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications

  2016cites this paper
• 99mTc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab

  2015cites this paper
• Exploration of peptide T7 and its derivative as integrin αvβ3-targeted imaging agents

  2015cites this paper
• 99mTc-3PRGD2 SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer

  2015cites this paper
• Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.

  2015cites this paper
• Impact of Multiple Negative Charges on Blood Clearance and Biodistribution Characteristics of 99mTc-Labeled Dimeric Cyclic RGD Peptides

  2014cites this paper
• FITC-Conjugated Cyclic RGD Peptides as Fluorescent Probes for Staining Integrin αvβ3/αvβ5 in Tumor Tissues

  2014cites this paper
• 99mTc-3P-RGD2 Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin αvβ3-Targeted Therapy

  2014cites this paper
• Biometabolic Distribution of 99mTc-3PRGD2 and its Potential Value in Monitoring Chemotherapeutic Effects

  2014cites this paper
• Molecular imaging agents for SPECT (and SPECT/CT)

  2014cites this paper
• Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2 Useful for Noninvasive Monitoring of Breast Tumor Response to Antiangiogenic Linifanib Therapy but not Anti-Integrin αvβ3 RGD2 Therapy

  2013cites this paper